Fig. 2: Clinical outcomes among cases with BA.2 and BA.4/BA.5 lineage SARS-CoV-2 infection, tested 29 April, 2022 to 29 July, 2022.
From: Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome
Plots illustrate cumulative 30-day risk of severe clinical outcomes among cases first ascertained in outpatient settings, stratified by SGTF status for infecting subvariant (BA.4/BA.5 [SGTF]: orange; BA.2 [No SGTF]: blue), for endpoints of any emergency department (ED) presentation (A); any inpatient admission (B); inpatient admission associated with an acute respiratory infection (ARI) diagnosis (C); intensive care unit (ICU) admission (D); mechanical ventilation (E), and death (F). Shaded areas denote 95% confidence intervals around median estimates (center lines). Plotted estimates indicate absolute risk of each outcome and do not include adjustment for confounding differences between cases with BA.2 and BA.4/BA.5 infection. Adjusted hazards ratios presented in Table 3 should thus be interpreted as measures of the independent association of infecting lineage with risk of each outcome. Data encompass outcomes among 106,532 SARS-CoV-2 cases (49,976 with BA.2 infections and 59,556 with BA.4/BA.5 infections).
